Evidence map›Paper›PMID 27583207›Full record

ArticleIDCases2016

Cytomegalic hepatitis in a patient receiving omalizumab.

R Gonçalves, C Valente, E Ferreira, J E Serra, J Saraiva da Cunha

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

R GonçalvesInfectious Diseases Unit - Centro Hospitalar e Universitário de Coimbra (Coimbrás Hospital Centre and University), Coimbra, Portugal.
C ValenteInfectious Diseases Unit - Centro Hospitalar e Universitário de Coimbra (Coimbrás Hospital Centre and University), Coimbra, Portugal.
E FerreiraInfectious Diseases Unit - Centro Hospitalar e Universitário de Coimbra (Coimbrás Hospital Centre and University), Coimbra, Portugal.
J E SerraInfectious Diseases Unit - Centro Hospitalar e Universitário de Coimbra (Coimbrás Hospital Centre and University), Coimbra, Portugal.
J Saraiva da CunhaInfectious Diseases Unit - Centro Hospitalar e Universitário de Coimbra (Coimbrás Hospital Centre and University), Coimbra, Portugal.
Hospitais da Universidade de Coimbra · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononucleosis syndrome with full recovery without specific treatment. We report a case of a 25 years old woman who presented with hepatitis due to CMV infection and history of omalizumab administration one month earlier. This recombinant monoclonal antibody is used to control refractory asthma and chronic spontaneous urticarial as it inhibits human IgE. Despite that, the long course of the disease lead us to initiate treatment with valganciclovir. The improvement after that was rapid and complete.

Indexed as

Cytomegalic hepatitisOmalizumabValganciclovir

Identifiers

PMID27583207
PMCPMC4995387
OpenAlexW2518268631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.